Business Wire

MITSUBISHI-HITACHI-POWER

2.4.2020 04:02:07 CEST | Business Wire | Press release

Share
MHPS: World’s Most Efficient Power Plant Is Synced to the Grid and Operating at Full Load, Ahead of Schedule

Mitsubishi Hitachi Power Systems, Ltd. (MHPS) has begun commissioning of T-Point 2, its new combined cycle power plant validation facility at Takasago Works in Hyogo Prefecture, Japan. Replacing the iconic T-Point, the facility will accelerate MHPS’ industry-leading technology and enable more robust validation of advanced-class gas turbines (ACGTs) such as the 1650°C-class JAC model and 1700°C-class ultrahigh-temperature models. Like its predecessor, T-Point 2 stands apart as the only facility in the world that performs full-scale long-term reliability verification for gas turbines. Connected to the actual grid, it is the only plant of its type in the world to function as both a technology demonstrator and an electric power producer and supplier. Also housed within Takasago Works are centers for R&D, design, manufacturing, and short-term component testing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005834/en/

“Through the years, we have proven our ability to develop and manufacture the most cutting-edge solutions for the power generation industry,” said Mr. Ken Kawai, President and CEO, MHPS. “Building on the legacy of the original T-Point, T-Point 2 will enable us to widen our footprint as the preferred solutions partner to meet ever-changing power generation requirements around the world.”

Engineering the next generation of gas turbines
Once commercial operations begin in July 2020, T-Point 2 is expected to achieve power output of over 566 MW (60Hz), with nearly 64% efficiency, 99.5% reliability and a world-first turbine inlet temperature of 1650°C – raising industry standards for gas turbine combined cycle performance globally. This improved performance is possible due to the advanced engineering of the upgraded J-Series Air-Cooled (JAC) model, which is the first gas turbine being validated at T-Point 2.

The new facility features a triple-casing steam turbine, augmenting overall system efficiency through a multiplier effect with the JAC gas turbine. This greater efficiency reduces carbon emissions and heat loss, significantly reducing the environmental impact of T-Point 2.

“The prototype validation system established by MHPS has given our customers the clear assurance that they are receiving the highest caliber and most reliable energy solutions in the market,” said Mr. Junichiro Masada, Senior Vice President and Senior General Manager of Gas Turbine Technology & Products Integration Division, MHPS. “The launch of T-Point 2 is testament to MHPS’ commitment to deliver industry-leading power generation technology and customer service underpinned by best-in-class methods for performance and durability verification.”

MHPS will use the facility to conduct validation of the next-generation 1700°C-class ultrahigh-temperature gas turbines, steam turbine upgrades, air-cooled condenser technology, generators, and static frequency converters.

Bringing power generation to the digital age
Work is underway to install and train advanced artificial intelligence technology at T-Point 2, which will feature the MHPS-TOMONI® suite of digital solutions. During the 8,000 hour durability demonstration period, MHPS will also be training its AI apps, allowing T-Point 2 to eventually become the world’s first autonomous combined cycle power plant. This will catapult power generation into a future where digital technologies are fully integrated into plant operations, allowing plant owners to leverage data to optimize performance, enable condition-based predictive maintenance for equipment, selectively automate operation and maintenance (O&M) decision-making, and reduce risk.

With these building blocks, MHPS will remotely monitor and manage total plant performance; remotely operate the plant in coordination with grid and fleet-wide energy management objectives; and utilize sensor and control system data to make smarter operation decisions in real time. MHPS-TOMONI® solutions powered by advanced technologies such as artificial intelligence and machine learning will enable MHPS to automate O&M decision-making to maximize the profitability of existing and future GTCC plants.

About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com . Follow us at https://twitter.com/MHPS_Global , or http://www.linkedin.com/showcase/mhps

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release

Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao​ Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit​ Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao.​ Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat

Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 08:49:00 CEST | Press release

IQM Radiance R1 is the first on-premises quantum computer for the PUT. The university aims to use the system to spearhead quantum education and research while boosting STEM in the country. This is the second operational quantum computer deployed in Poland by IQM. The university recognizes the significant long-term potential of integrating quantum computing, artificial intelligence, and high-performance computing (HPC), and intends to play a key role in shaping this transformation in Europe. Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weyde

BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 08:30:00 CEST | Press release

BearingPoint is expanding its AI portfolio with a fully owned, sovereign on-premise and edge infrastructure designed specifically for generative and agentic AI workloads in highly regulated industries and public administrations in Europe. Building on decades of experience operating its own sovereign cloud, the firm now offers clients both dedicated hardware and token-based access to large language models – fully GDPR-compliant, ISO-certified and, on request, NIS2- and DORA-ready BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical sc

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release

Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho

Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release

Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye